Pharvaris (NASDAQ:PHVS) Earns Buy Rating from Analysts at HC Wainwright

Key Points

• Analysts at HC Wainwright have issued a "buy" rating for Pharvaris (NASDAQ:PHVS) with a price target of $60.00, suggesting a potential upside of 175.48% from its current trading price.
• The consensus rating for Pharvaris is a "Moderate Buy" with a consensus price target of $37.17, as several research firms have varied ratings on the stock.
• Pharvaris recently reported an earnings per share (EPS) of ($0.94), missing analyst expectations, and is projected to post an EPS of (-2.71) for the current fiscal year.

Stock analysts at HC Wainwright assumed coverage on shares of Pharvaris (NASDAQ:PHVS - Get Free Report) in a report released on Wednesday, MarketBeat reports. The firm set a "buy" rating and a $60.00 price target on the stock. HC Wainwright's price target indicates a potential upside of 175.48% from the company's current price.

PHVS has been the subject of a number of other research reports. Zacks Research raised Pharvaris from a "strong sell" rating to a "hold" rating in a report on Monday, August 18th. Bank of America raised Pharvaris from an "underperform" rating to a "neutral" rating and upped their price target for the stock from $16.00 to $27.00 in a research note on Thursday, October 9th. JMP Securities lowered their price target on Pharvaris from $55.00 to $52.00 and set a "market outperform" rating on the stock in a report on Wednesday, August 13th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pharvaris in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $37.17.

Pharvaris Trading Up 3.9%

PHVS stock opened at $21.78 on Wednesday. The stock has a market capitalization of $1.14 billion, a P/E ratio of -6.48 and a beta of -2.77. Pharvaris has a 12 month low of $11.51 and a 12 month high of $26.33. The firm has a 50-day moving average price of $22.98 and a 200-day moving average price of $19.27.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.07). As a group, equities analysts predict that Pharvaris will post -2.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharvaris

Institutional investors and hedge funds have recently modified their holdings of the business. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in Pharvaris during the 2nd quarter valued at $57,000. JPMorgan Chase & Co. raised its position in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock worth $59,000 after acquiring an additional 783 shares in the last quarter. Legal & General Group Plc raised its position in shares of Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company's stock worth $203,000 after acquiring an additional 1,695 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Pharvaris by 9.8% in the 2nd quarter. California State Teachers Retirement System now owns 14,048 shares of the company's stock worth $247,000 after acquiring an additional 1,257 shares in the last quarter. Finally, Palumbo Wealth Management LLC raised its position in shares of Pharvaris by 38.0% in the 1st quarter. Palumbo Wealth Management LLC now owns 14,102 shares of the company's stock worth $221,000 after acquiring an additional 3,881 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.